Playing Nice Over REMS: FDA Sees Accutane As Model For Shared Systems
Executive Summary
FDA will use the Accutane risk management agreement between Roche and generic drug companies as a guide for implementing the Risk Evaluation & Mitigation Strategy "shared use" provision of the FDA Amendments Act
You may also be interested in...
iPLEDGE Again On FDA Advisory Agenda, This Time As An Example
"REMS-related topics" is the theme of a joint FDA advisory committee meeting Dec. 1 focused on the landmark iPLEDGE program as an example of the effect such programs have on the health care system.
REMS: Added Expense For Pharma, Increased Opportunity For Vendors
The first anniversary of REMS is March 25: one year from the effective date of the FDA Amendments Act provisions granting FDA authority to require Risk Evaluation and Mitigation Strategies for drugs that raise safety issues.
REMS: Added Expense For Pharma, Increased Opportunity For Vendors
The first anniversary of REMS is March 25: one year from the effective date of the FDA Amendments Act provisions granting FDA authority to require Risk Evaluation and Mitigation Strategies for drugs that raise safety issues.